课题基金 / 基金详情

项目摘要

项目成果

PAUL M LIEBERMAN的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结(参见说明):GhlP-Seq Production核心将负责1)执行ChIP测定; 2)生成用于Illumina下一代测序的文库,3)将序列数据映射到KSHV和人类基因组,以及4)提供后续生物信息学分析。这些目标将是。这是与Wistar研究所基因组学和生物信息学核心联合完成的,该核心提供Illumina下一代测序作为核心服务。最终数据管理和分析将通过KSHV的共享网络浏览器提供给每名项目研究者。在ChIP、下一代测序和生物信息学支持的各个方面的专业知识将在赠款支持的生命周期内提供给这些项目。GhlP-Seq核心将由Paul Lieberman博士领导,他熟悉ChIP Seq方法和应用于KSHV和EBV基因组的生物信息学分析。ChIP-Seq核心将促进该计划项目的所有成员标准化样品制备和测序后分析方法的能力。这项工作将在Wistar研究所的Lieberman实验室内进行;并与Wistar研究所基因组学核心和测序设施一起进行。
英文摘要
PROJECT SUMMARY (See instructions): The GhlP-Seq Production core will be responsible for 1) performing ChlP-assays; 2) generating library for lllumina next-generation sequencing, 3) mapping sequence data to KSHV and human genomes, and 4) providing follow-up bioinformatics analyses. These goals will be. accomplished in conjunction with the Wistar Institutes Genomics and Bioinformatics Core, which provides lllumina Next Generation Sequencing as a core service. Final data management and analyses will be made accessible to each project investigator via a shared web-based browser for KSHV. Expertise in all aspects of ChIP, Next-Generation Sequencing, and Bioinformatic support will be provided to the projects for the lifetime of grant support. The GhlP-Seq core will be lead by Dr. Paul Lieberman, who is familler with ChIP Seq methods and bioinformatics analyses as applied to KSHV and EBV genomes. The ChlP-Seq core will facilitate the ability of all members of the Program project to standardize, methods for sample preparation and for post-sequence analysis. The work will be performed at the Wistar Institute in space within the Lieberman lab; and in conjunction with the Wistar Institute Genomics Core and Sequencing facility.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 4: Regulation of EBV Latency and Oncogenesis by Hypoxia
  • 批准号:
    10714176
  • 项目类别:
  • 资助金额:
    $47.49万
  • 财政年份:
    2023
  • 负责人:
    PAUL M LIEBERMAN
  • 依托单位:
Epigenomic Drivers of EBV Epithelial Cancers
  • 批准号:
    10627690
  • 项目类别:
  • 资助金额:
    $46.97万
  • 财政年份:
    2023
  • 负责人:
    PAUL M LIEBERMAN
  • 依托单位:
Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
  • 批准号:
    10627689
  • 项目类别:
  • 资助金额:
    $243.61万
  • 财政年份:
    2023
  • 负责人:
    PAUL M LIEBERMAN
  • 依托单位:
EBNA1 Inhibitor for Treatment of EBV-positive DLBCL
  • 批准号:
    10719866
  • 项目类别:
  • 资助金额:
    $74.58万
  • 财政年份:
    2023
  • 负责人:
    PAUL M LIEBERMAN
  • 依托单位:
海外基金